Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 139

1.

Phenotype characterization of human melanoma cells resistant to dabrafenib.

Cordaro FG, De Presbiteris AL, Camerlingo R, Mozzillo N, Pirozzi G, Cavalcanti E, Manca A, Palmieri G, Cossu A, Ciliberto G, Ascierto PA, Travali S, Patriarca EJ, Caputo E.

Oncol Rep. 2017 Nov;38(5):2741-2751. doi: 10.3892/or.2017.5963. Epub 2017 Sep 18.

2.

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.

Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL; MMAIT-IV Clinical Trial Group.

Ann Surg Oncol. 2017 Dec;24(13):3991-4000. doi: 10.1245/s10434-017-6072-3. Epub 2017 Oct 10.

PMID:
29019177
3.

Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma.

Nelson DW, Stern S, Elashoff DE, Elashoff R, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Cochran AJ, Faries MB.

J Am Coll Surg. 2017 Aug;225(2):302-311. doi: 10.1016/j.jamcollsurg.2017.05.013. Epub 2017 Jun 28.

PMID:
28668274
4.

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM.

N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.

5.

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis.

Di Monta G, Caracò C, Simeone E, Grimaldi AM, Marone U, Di Marzo M, Vanella V, Festino L, Palla M, Mori S, Mozzillo N, Ascierto PA.

J Transl Med. 2017 Apr 26;15(1):82. doi: 10.1186/s12967-017-1186-8.

6.

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.

Simeone E, Grimaldi AM, Festino L, Giannarelli D, Vanella V, Palla M, Curvietto M, Esposito A, Palmieri G, Mozzillo N, Ascierto PA.

Oncoimmunology. 2017 Jan 19;6(3):e1283462. doi: 10.1080/2162402X.2017.1283462. eCollection 2017.

7.

The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma.

Jones MS, Jones PC, Stern SL, Elashoff D, Hoon DSB, Thompson J, Mozzillo N, Nieweg OE, Noyes D, Hoekstra HJ, Zager JS, Roses DF, Testori A, Coventry BJ, Smithers MB, Andtbacka R, Agnese D, Schultz E, Hsueh EC, Kelley M, Schneebaum S, Jacobs L, Bowles T, Kashani-Sabet M, Johnson D, Faries MB.

Ann Surg Oncol. 2017 Aug;24(8):2089-2094. doi: 10.1245/s10434-017-5775-9. Epub 2017 Feb 21.

PMID:
28224364
8.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

9.

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.

Ascierto PA, Vanella V, Grimaldi AM, Lucia F, Palla M, Simeone E, Mozzillo N.

Cancer Immunol Immunother. 2016 Nov;65(11):1395-1400. Epub 2016 Sep 7.

PMID:
27604993
10.

Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors.

Campana LG, Testori A, Curatolo P, Quaglino P, Mocellin S, Framarini M, Borgognoni L, Ascierto PA, Mozzillo N, Guida M, Bucher S, Rotunno R, Marenco F, De Salvo GL, De Paoli A, Rossi CR, Bonadies A.

Eur J Surg Oncol. 2016 Dec;42(12):1914-1923. doi: 10.1016/j.ejso.2016.06.399. Epub 2016 Jun 29.

11.

Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma.

Apice G, Pizzolorusso A, Di Maio M, Grignani G, Gebbia V, Buonadonna A, De Chiara A, Fazioli F, De Palma G, Galizia D, Arcara C, Mozzillo N, Perrone F.

Sarcoma. 2016;2016:6862090. doi: 10.1155/2016/6862090. Epub 2016 Feb 25.

12.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

13.

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.

Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Caracò C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascierto PA.

Oncoimmunology. 2015 May 22;4(6):e1008842. eCollection 2015 Jun.

14.

Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.

Mozzillo N, Pasquali S, Santinami M, Testori A, Di Marzo M, Crispo A, Patuzzo R, Verrecchia F, Botti G, Montella M, Rossi CR, Caracò C.

Eur J Surg Oncol. 2015 Jul;41(7):823-9. doi: 10.1016/j.ejso.2015.02.005. Epub 2015 Mar 11.

PMID:
25800935
15.

Report from the second MIB (Melanoma Independent Board) Conference, 27-28 October 2014.

Testori A, Rossi CR, Ascierto P, de Lorenzo F, Mozzillo N.

Ecancermedicalscience. 2015 Feb 19;9:511. doi: 10.3332/ecancer.2015.511. eCollection 2015.

16.

Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.

Grimaldi AM, Simeone E, Palla M, Festino L, Caracò C, Mozzillo N, Petrillo A, Muto P, Ascierto PA.

Anticancer Drugs. 2015 Apr;26(4):464-8. doi: 10.1097/CAD.0000000000000206.

PMID:
25622086
17.

Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.

Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travali S.

Cancer Lett. 2015 Feb 1;357(1):286-296. doi: 10.1016/j.canlet.2014.11.033. Epub 2014 Nov 20.

18.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2014 Oct 28;12:277. doi: 10.1186/s12967-014-0277-z.

19.

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, Esposito A, Paone M, Palla M, Palmieri G, Caracò C, Ciliberto G, Mozzillo N, Ascierto PA.

Oncoimmunology. 2014 May 14;3:e28780. eCollection 2014.

20.

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.

Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA.

J Transl Med. 2014 Jul 31;12:216. doi: 10.1186/s12967-014-0216-z.

Supplemental Content

Loading ...
Support Center